Skip to content

Clinical Evaluation of Biomedics Monthly Sphere and Avaira Vitality Sphere

Clinical Evaluation of Biomedics Monthly Sphere and Avaira Vitality Sphere

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06400914
Enrollment
44
Registered
2024-05-06
Start date
2024-04-03
Completion date
2024-05-11
Last updated
2025-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ametropia

Brief summary

The aim of this study is to compare the short-term clinical performance of two sphere contact lenses.

Detailed description

The aim of this study is to evaluate the short-term clinical performance of two different sphere contact lenses after 15 minutes of daily wear each.

Interventions

15 minutes of daily wear.

15 minutes of daily wear.

Sponsors

Centre for Ocular Research & Education, Canada
CollaboratorOTHER
CooperVision, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Is at least 18 years of age and has full legal capacity to volunteer. 2. Has read and signed an information consent letter. 3. Self-reports having a full eye examination in the previous two years. 4. Anticipates being able to wear the study lenses for the required time of the study. 5. Is willing and able to follow instructions and maintain the appointment schedule. 6. Has refractive astigmatism no higher than -0.75 DC. 7. Can be fit with the available lens parameters (sphere +6.00 to -10.00D). 8. Can achieve binocular distance vision of at least 20/30 Snellen (logMAR 0.18) with the study contact lenses.

Exclusion criteria

1. Is participating in any concurrent clinical or research study. 2. Has any known active ocular disease and/or infection that contraindicates contact lens wear. 3. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable. 4. Is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable. 5. Has known sensitivity to the diagnostic sodium fluorescein used in the study. 6. Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment. 7. Has undergone refractive error surgery or intraocular surgery.

Design outcomes

Primary

MeasureTime frameDescription
Lens Fit Acceptance RatingsAt the end of 15 Minutes of wearOverall lens fit acceptance was measured on a scale from 0-4 (0=Should not be worn and 4= Perfect)

Countries

Mexico

Participant flow

Pre-assignment details

Forty-four participants were screened and dispensed lenses. All participants who were dispensed with lenses completed the study. (n=44)

Participants by arm

ArmCount
All Study Participants
Includes all study participants
44
Total44

Baseline characteristics

CharacteristicAll Study Participants
Age, Continuous27.7 years
STANDARD_DEVIATION 9
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
36 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 440 / 44
other
Total, other adverse events
0 / 440 / 44
serious
Total, serious adverse events
0 / 440 / 44

Outcome results

Primary

Lens Fit Acceptance Ratings

Overall lens fit acceptance was measured on a scale from 0-4 (0=Should not be worn and 4= Perfect)

Time frame: At the end of 15 Minutes of wear

Population: All the forty-four participants who started the study, completed the study.

ArmMeasureValue (MEAN)Dispersion
Lens A (Ocufilcon D)Lens Fit Acceptance Ratings3.3 Units on ScaleStandard Deviation 1.1
Lens B (Fanfilcon A)Lens Fit Acceptance Ratings3.7 Units on ScaleStandard Deviation 0.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026